Have a feature idea you'd love to see implemented?
Let us know!
CHRS Coherus BioSciences Inc
Price (delayed)
$1.1
Market cap
$126.73M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.03
Enterprise value
$297.29M
Coherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients' lives and to deliver significant savings
Highlights
The net income has soared by 100% YoY and by 98% from the previous quarter
Coherus BioSciences's EPS has surged by 99% YoY and by 91% QoQ
The equity has grown by 34% YoY but it has contracted by 4.6% from the previous quarter
Coherus BioSciences's gross margin has decreased by 23% YoY but it has increased by 8% QoQ
Coherus BioSciences's quick ratio has decreased by 31% YoY
Key stats
What are the main financial stats of CHRS
Market
Valuations
Earnings
Shares outstanding
115.21M
Market cap
$126.73M
Enterprise value
$297.29M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.42
EV/EBIT
9.3
EV/EBITDA
7.88
EV/Sales
0.98
Revenue
$304.34M
EBIT
$31.98M
EBITDA
$37.75M
Free cash flow
-$61.94M
Per share
Balance sheet
Liquidity
EPS
-$0.03
Free cash flow per share
-$0.54
Book value per share
-$0.76
Revenue per share
$2.64
TBVPS
$3.91
Total assets
$505M
Total liabilities
$592.97M
Debt
$268.25M
Equity
-$87.97M
Working capital
$73.46M
Debt to equity
-3.05
Current ratio
1.25
Quick ratio
1
Net debt/EBITDA
4.52
Margins
Efficiency
Dividend
EBITDA margin
12.4%
Gross margin
44.7%
Net margin
-0.1%
Operating margin
-45.5%
Return on assets
-0.1%
Return on equity
N/A
Return on invested capital
8.1%
Return on capital employed
15.3%
Return on sales
10.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CHRS stock price
How has the Coherus BioSciences stock price performed over time
Intraday
0%
1 week
42.38%
1 month
25.6%
1 year
-44.72%
YTD
-66.97%
QTD
5.77%
Financial performance
How have Coherus BioSciences's revenue and profit performed over time
Revenue
$304.34M
Gross profit
$136.08M
Operating income
-$138.33M
Net income
-$450,000
Gross margin
44.7%
Net margin
-0.1%
The net income has soared by 100% YoY and by 98% from the previous quarter
The net margin has soared by 100% year-on-year and by 99% since the previous quarter
The company's operating margin rose by 48% YoY and by 14% QoQ
The revenue rose by 44% year-on-year
Growth
What is Coherus BioSciences's growth rate over time
Valuation
What is Coherus BioSciences stock price valuation
P/E
N/A
P/B
N/A
P/S
0.42
EV/EBIT
9.3
EV/EBITDA
7.88
EV/Sales
0.98
Coherus BioSciences's EPS has surged by 99% YoY and by 91% QoQ
The equity has grown by 34% YoY but it has contracted by 4.6% from the previous quarter
The P/S is 83% below the 5-year quarterly average of 2.4 and 48% below the last 4 quarters average of 0.8
The revenue rose by 44% year-on-year
Efficiency
How efficient is Coherus BioSciences business performance
CHRS's return on invested capital has surged by 133% year-on-year
Coherus BioSciences's return on sales has surged by 112% YoY
The return on assets has surged by 100% year-on-year and by 98% since the previous quarter
Dividends
What is CHRS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CHRS.
Financial health
How did Coherus BioSciences financials performed over time
The total assets is 15% less than the total liabilities
The current ratio has contracted by 32% YoY but it has grown by 3.3% from the previous quarter
Coherus BioSciences's quick ratio has decreased by 31% YoY
The debt has declined by 43% year-on-year
The equity has grown by 34% YoY but it has contracted by 4.6% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.